Company Profile
Nuvalent Stock Price, News & Analysis
- Ticker:
- NUVL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
123.96 USD (+0.02%)
Close
Last updated: July 14, 2026
7.22B USD
Market cap
Why the stock is moving
Current closing-price context is not available for NUVL.
Company overview
Business overview
Nuvalent is a precision-oncology company developing next-generation kinase inhibitors for genetically defined cancers.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Nuvalent sits in targeted oncology biotechnology.
Business Model Characteristics
The company depends on differentiated clinical data, molecule design, and the possibility of building best-in-class oncology assets.
Position Within the Biotechnology Landscape
Nuvalent is a high-quality targeted-therapy name whose stock reacts quickly to efficacy and safety differentiation.
Future catalysts
Nuvalent's catalysts are NVL-655 in ALK and NVL-520 in ROS1, where selectivity and tolerability data decide whether the next-gen kinase story keeps its premium. The company still needs each update to reinforce its differentiation.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Nuvalent (NUVL)?
Nuvalent (NUVL) most recently closed at 123.96 USD, a +0.02% move versus the previous session.
What is the market cap of Nuvalent (NUVL)?
Nuvalent currently has a market capitalization of 7.22B USD on BioPharmSignal.
What does Nuvalent do?
Nuvalent is a precision-oncology company developing next-generation kinase inhibitors for genetically defined cancers.
On which exchange is NUVL stock listed?
Nuvalent (NUVL) is associated with NASDAQ, United States, Biopharma.
What is NVL-655?
Nuvalent's catalysts are NVL-655 in ALK and NVL-520 in ROS1, where selectivity and tolerability data decide whether the next-gen kinase story keeps its premium.
Which conditions is Nuvalent targeting with NVL-655?
Nuvalent is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Nuvalent describe recent progress with NVL-655?
Nuvalent's catalysts are NVL-655 in ALK and NVL-520 in ROS1, where selectivity and tolerability data decide whether the next-gen kinase story keeps its premium.
What is NVL-520?
Nuvalent's catalysts are NVL-655 in ALK and NVL-520 in ROS1, where selectivity and tolerability data decide whether the next-gen kinase story keeps its premium.